Bioage Labs identifies new NLRP3 inflammasome inhibitors
Oct. 20, 2022
Bioage Labs Inc. has synthesized new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndromes, hearing loss, Ménière's disease, tinnitus, vertigo and inflammatory disorders.